A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
NCT ID: NCT03055611
Last Updated: 2024-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
201 participants
OBSERVATIONAL
2017-05-09
2022-04-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)
NCT06158334
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
NCT03901755
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
NCT02976753
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
NCT03655340
Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
NCT03272568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Haemophilia A patients
Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
ELOCTA
Extended half-life factor VIII product
Haemophilia B patients
Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
ALPROLIX
Extended half-life factor IX product
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELOCTA
Extended half-life factor VIII product
ALPROLIX
Extended half-life factor IX product
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have started prophylactic Elocta/Alprolix treatment prior to enrollment visit, or at enrollment prescribed prophylactic treatment with Elocta or Alprolix regardless of participation in the study
* Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, Before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swedish Orphan Biovitrum
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Physician, MD
Role: STUDY_DIRECTOR
Swedish Orphan Biovitrum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swedish Orphan Biovitrum Reserach site
Berlin, , Germany
Swedish Orphan Biovitrum Reserach Site
Blaubeuren Abbey, , Germany
Swedish Orphan Biovitrum Research Site
Bonn, , Germany
Swedish Orphan Biovitrum Research Site
Delmenhorst, , Germany
Swedish Orphan Biovitrum Research Site
Duisburg, , Germany
Swedish Orphan Biovitrum Reserach site
Erlangen, , Germany
Swedish Orphan Biovitrum Research Site
Frankfurt, , Germany
Swedish Orphan Biovitrum Reserach site
Frankfurt, , Germany
Swedish Orphan Biovitrum Research Site
Fürth, , Germany
Swedish Orphan Biovitrum Research Site
Hamburg, , Germany
Swedish Orphan Biovitrum Research Site
Hanover, , Germany
Swedish Orphan Biovitrum Reserach site
Hanover, , Germany
Swedish Orphan Biovitrum Reserach site
Heidelberg, , Germany
Swedish Orphan Biovitrum Reserach site
Homburg, , Germany
Swedish Orphan Biovitrum Research Site
Jena, , Germany
Swedish Orphan Biovitrum Reserach Site
Jena, , Germany
Swedish Orphan Biovitrum Reserach site
Leipzig, , Germany
Swedish Orphan Biovitrum Reserach Site
Mörfelden-Walldorf, , Germany
Swedish Orphan Biovitrum Research Site
München, , Germany
Swedish Orphan Biovitrum Reserach site
München, , Germany
Swedish Orphan Biovitrum Reserach site
Münster, , Germany
Swedish Orphan Biovitrum Research Site
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sobi.HAEM89-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.